Eledon Pharmaceuticals Stock Buy Hold or Sell Recommendation
| ELDN Stock | USD 4.26 0.01 0.24% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Eledon Pharmaceuticals is 'Sell'. The recommendation algorithm takes into account all of Eledon Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site.
Check out Eledon Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide. In addition, we conduct extensive research on individual companies such as Eledon and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Eledon |
Execute Eledon Pharmaceuticals Buy or Sell Advice
The Eledon recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Eledon Pharmaceuticals. Macroaxis does not own or have any residual interests in Eledon Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Eledon Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Good | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Eledon Pharmaceuticals Trading Alerts and Improvement Suggestions
| Eledon Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (40.33 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eledon Pharmaceuticals currently holds about 70.46 M in cash with (39.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.12, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Eledon Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Gros David-alexandre C of 1015743 shares of Eledon Pharmaceuticals at 2.3 subject to Rule 16b-3 |
Eledon Pharmaceuticals current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Eledon analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Eledon analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Eledon Pharmaceuticals Returns Distribution Density
The distribution of Eledon Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Eledon Pharmaceuticals' future price movements. The chart of the probability distribution of Eledon Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Eledon Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Eledon Pharmaceuticals returns is essential to provide solid investment advice for Eledon Pharmaceuticals.
| Mean Return | 0.71 | Value At Risk | -4.24 | Potential Upside | 10.09 | Standard Deviation | 4.75 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Eledon Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Eledon Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Eledon Pharmaceuticals, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Eledon Pharmaceuticals back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Cm Management, Llc | 2024-09-30 | 275 K | State Street Corp | 2024-06-30 | 161.5 K | Blackrock Inc | 2024-06-30 | 155.1 K | Renaissance Technologies Corp | 2024-09-30 | 135.9 K | Northern Trust Corp | 2024-09-30 | 91.9 K | Ubs Group Ag | 2024-06-30 | 55 K | Ingalls & Snyder Llc | 2024-09-30 | 51.8 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 34.2 K | Bridgeway Capital Management, Llc | 2024-09-30 | 33.4 K | Bvf Inc | 2024-09-30 | 6.3 M | Armistice Capital, Llc | 2024-09-30 | 2.4 M |
Eledon Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (4.2M) | 105.4M | (29.4M) | (28.4M) | (51.8M) | (49.2M) | |
| Free Cash Flow | (13.9M) | (15.2M) | (28.9M) | (28.4M) | (39.5M) | (37.6M) | |
| Depreciation | 182K | 183K | 195K | 373K | 374K | 392.7K | |
| Other Non Cash Items | 1.9M | 4.8M | 6.2M | 48.6M | 8.7M | 6.5M | |
| Net Income | (16.0M) | (22.8M) | (34.5M) | (88.0M) | (40.3M) | (42.3M) | |
| End Period Cash Flow | 8.8M | 114.2M | 84.8M | 56.4M | 4.6M | 4.4M | |
| Change To Netincome | 1.5M | 3.2M | 7.6M | 5.6M | 6.4M | 3.5M |
Eledon Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Eledon Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Eledon Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Eledon stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.70 | |
β | Beta against Dow Jones | 0.04 | |
σ | Overall volatility | 4.84 | |
Ir | Information ratio | 0.12 |
Eledon Pharmaceuticals Volatility Alert
Eledon Pharmaceuticals shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Eledon Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Eledon Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Eledon Pharmaceuticals Fundamentals Vs Peers
Comparing Eledon Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Eledon Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Eledon Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Eledon Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Eledon Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Eledon Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Eledon Pharmaceuticals to competition |
| Fundamentals | Eledon Pharmaceuticals | Peer Average |
| Return On Equity | -0.25 | -0.31 |
| Return On Asset | -0.33 | -0.14 |
| Current Valuation | 176.8 M | 16.62 B |
| Shares Outstanding | 59.74 M | 571.82 M |
| Shares Owned By Insiders | 0.04 % | 10.09 % |
| Shares Owned By Institutions | 42.88 % | 39.21 % |
| Number Of Shares Shorted | 731.49 K | 4.71 M |
| Price To Book | 3.35 X | 9.51 X |
| EBITDA | (42.63 M) | 3.9 B |
| Net Income | (40.33 M) | 570.98 M |
| Cash And Equivalents | 70.46 M | 2.7 B |
| Cash Per Share | 5.12 X | 5.01 X |
| Total Debt | 383 K | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 22.22 X | 2.16 X |
| Book Value Per Share | 1.85 X | 1.93 K |
| Cash Flow From Operations | (39.53 M) | 971.22 M |
| Short Ratio | 0.88 X | 4.00 X |
| Earnings Per Share | 0.73 X | 3.12 X |
| Price To Earnings To Growth | 0.01 X | 4.89 X |
| Target Price | 12.5 | |
| Number Of Employees | 20 | 18.84 K |
| Beta | 0.77 | -0.15 |
| Market Capitalization | 254.49 M | 19.03 B |
| Total Asset | 125.89 M | 29.47 B |
| Retained Earnings | (243.19 M) | 9.33 B |
| Working Capital | 52.23 M | 1.48 B |
| Net Asset | 125.89 M |
Note: Acquisition by Gros David-alexandre C of 1015743 shares of Eledon Pharmaceuticals at 2.3 subject to Rule 16b-3 [view details]
Eledon Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Eledon . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.0481 | |||
| Daily Balance Of Power | 0.0476 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 4.27 | |||
| Day Typical Price | 4.26 | |||
| Market Facilitation Index | 0.21 | |||
| Period Momentum Indicator | 0.01 |
About Eledon Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Eledon Pharmaceuticals? Buying financial instruments such as Eledon Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Eledon Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corporate ETFs Thematic Idea Now
Corporate ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Corporate ETFs theme has 222 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Eledon Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.73 | Return On Assets (0.33) | Return On Equity (0.25) |
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.